Mechanistic and therapeutic overview of glycosaminoglycans: The unsung heroes of biomolecular signaling

Glycoconjugate Journal

Volumn 33, Issue 1, 2016, Pages 1-17

  Gulati, Khushboo ^a   Poluri, Krishna Mohan ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

GAG Therapeutics; GAGome; Glycoimmunology; Glycosaminoglycans; Nanocomposites; Regenerative medicine

Indexed keywords

BIOLOGICAL MARKER; CARBOHYDRATE; CHITOSAN; GLYCEROPHOSPHATE; GLYCOSAMINOGLYCAN; HEPARIN; HYALURONIC ACID; KERATAN SULFATE; NANOCOMPOSITE; NUTRACEUTICAL; PROTEOGLYCAN;

ARTICLE; BIOTECHNOLOGY; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; HUMAN; MOLECULAR RECOGNITION; NANOBIOTECHNOLOGY; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SURFACE PROPERTY; TISSUE ENGINEERING; ANIMAL; CARBOHYDRATE METABOLISM, INBORN ERRORS; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; METABOLISM;

ANIMALS; CARBOHYDRATE METABOLISM, INBORN ERRORS; GLYCOSAMINOGLYCANS; HUMANS; IMMUNE SYSTEM DISEASES; SIGNAL TRANSDUCTION;

EID: 84955638427     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-015-9642-2     Document Type: Article

References (240)

1. Baum, L.G.; Crocker, P.R.: Glycoimmunology: ignore at your peril! Immunol. Rev. 230, 5-8 (2009)
2. Manon-Jensen, T.; Itoh, Y.; Couchman, J.R.: Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 277, 3876-3889 (2010)
3. Smith, P.D.; Coulson-Thomas, V.J.; Foscarin, S.; Kwok, J.C.; Fawcett, J.W.: "GAG-ing with the neuron": The role of glycosaminoglycan patterning in the central nervous system. Exp. Neurol. (2015) (In press)
4. Yung, S.; Chan, T.M.: Glycosaminoglycans and proteoglycans: overlooked entities? Perit. Dial. Int. 27(Suppl 2), S104-S109 (2007)
5. Parish, C.R.: The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6, 633-643 (2006)
6. Simon Davis, D.A.; Parish, C.R.: Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity. Front. Immunol. 4, 470 (2013)
7. Zhang, L.: Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. Prog. Mol. Biol. Transl. Sci. 93, 1-17 (2010)
8. Afratis, N.; Gialeli, C.; Nikitovic, D.; et al.: Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 279, 1177-1197 (2012)
9. Ariga, T.; Miyatake, T.; Yu, R.K.: Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: amyloidogenesis and therapeutic strategies - a review. J. Neurosci. Res. 88, 2303-2315 (2010)
10. Kamhi, E.; Joo, E.J.; Dordick, J.S.; Linhardt, R.J.: Glycosaminoglycans in infectious disease. Biol. Rev. Camb. Philos. Soc. 88, 928-943 (2013)
11. Papy-Garcia, D.; Christophe, M.; Huynh, M.B.; et al.: Glycosaminoglycans, protein aggregation and neurodegeneration. Curr. Protein Pept. Sci. 12, 258-268 (2011)
12. Tiwari, V.; Maus, E.; Sigar, I.M.; Ramsey, K.H.; Shukla, D.: Role of heparan sulfate in sexually transmitted infections. Glycobiology 22, 1402-1412 (2012)
13. Hirano, K.; Ohgomori, T.; Kobayashi, K.; et al.: Ablation of keratan sulfate accelerates early phase pathogenesis of ALS. PLoS One 8, e66969 (2013)
14. Weiser, P.; Qian, Y.; Pan, J.; et al.: Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases. Prog. Mol. Biol. Transl. Sci. 93, 443-472 (2010)
15. van de Lest, C.H.; Versteeg, E.M.; Veerkamp, J.H.; et al.: Altered composition of urinary heparan sulfate in patients with COPD. Am. J. Respir. Crit. Care Med. 154, 952-958 (1996)
16. Esko, J.D.; Kimata, K.; Lindahl, U.: Proteoglycans and Sulfated Glycosaminoglycans. Essentials of Glycobiology 2nd edn, 229-248 (2009)
17. Vigetti, D.; Karousou, E.; Viola, M.; Deleonibus, S.; De, L.G.; Passi, A.: Hyaluronan: biosynthesis and signaling. Biochim. Biophys. Acta 1840, 2452-2459 (2014)
18. Sasisekharan, R.; Venkataraman, G.: Heparin and heparan sulfate: biosynthesis, structure and function. Curr. Opin. Chem. Biol. 4, 626-631 (2000)
19. Mikami, T.; Kitagawa, H.: Biosynthesis and function of chondroitin sulfate. Biochim. Biophys. Acta 1830, 4719-4733 (2013)
20. Li, L.; Ly, M.; Linhardt, R.J.: Proteoglycan sequence. Mol. Biosyst. 8, 1613-1625 (2012)
21. Sugahara, K.; Kitagawa, H.: Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr. Opin. Struct. Biol. 10, 518-527 (2000)
22. Bulow, H.E.; Hobert, O.: The molecular diversity of glycosaminoglycans shapes animal development. Annu. Rev. Cell Dev. Biol. 22, 375-407 (2006)
23. Habuchi, H.; Habuchi, O.; Kimata, K.: Sulfation pattern in glycosaminoglycan: does it have a code? Glycoconj. J. 21, 47-52 (2004)
24. Funderburgh, J.L.: Keratan sulfate biosynthesis. IUBMB Life 54, 187-194 (2002)
25. Pomin, V.H.: Keratan sulfate: an up-to-date review. Int. J. Biol. Macromol. 72, 282-289 (2015)
26. Iozzo, R.V.; Schaefer, L.: Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 42, 11-55 (2015)
27. Billings, P.C.; Pacifici, M.: Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries. Connect. Tissue Res. 56, 272-280 (2015)
28. Lee-Sayer, S.S.; Dong, Y.; Arif, A.A.; Olsson, M.; Brown, K.L.; Johnson, P.: The where, when, how, and why of hyaluronan binding by immune cells. Front. Immunol. 6, 150 (2015)
29. Mizumoto, S.; Yamada, S.; Sugahara, K.: Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins. Curr. Opin. Struct. Biol. 34, 35-42 (2015)
30. Pomin, V.H.; Mulloy, B.: Current structural biology of the heparin interactome. Curr. Opin. Struct. Biol. 34, 17-25 (2015)
31. Kawashima, H.; Hirose, M.; Hirose, J.; Nagakubo, D.; Plaas, A.H.; Miyasaka, M.: Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J. Biol. Chem. 275, 35448-35456 (2000)
32. Nelson, R.M.; Cecconi, O.; Roberts, W.G.; Aruffo, A.; Linhardt, R.J.; Bevilacqua, M.P.: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82, 3253-3258 (1993)
33. Siegelman, M.H.; DeGrendele, H.C.; Estess, P.: Activation and interaction of CD44 and hyaluronan in immunological systems. J. Leukoc. Biol. 66, 315-321 (1999)
34. Gandhi, N.S.; Coombe, D.R.; Mancera, R.L.: Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans: 1. Molecular modeling studies. Biochemistry 47, 4851-4862 (2008)
35. Cole, G.J.; Loewy, A.; Glaser, L.: Neuronal cell-cell adhesion depends on interactions of N-CAM with heparin-like molecules. Nature 320, 445-447 (1986)
36. Coombe, D.R.; Watt, S.M.; Parish, C.R.: Mac-1 (CD11b/CD18) and CD45 mediate the adhesion of hematopoietic progenitor cells to stromal cell elements via recognition of stromal heparan sulfate. Blood 84, 739-752 (1994)
37. Izumikawa, T.; Sato, B.; Kitagawa, H.: Chondroitin sulfate is indispensable for pluripotency and differentiation of mouse embryonic stem cells. Sci. Rep. 4, 3701 (2014)
38. Mikami, T.; Yasunaga, D.; Kitagawa, H.: Contactin-1 is a functional receptor for neuroregulatory chondroitin sulfate-E. J. Biol. Chem. 284, 4494-4499 (2009)
39. Koike, T.; Izumikawa, T.; Tamura, J.; Kitagawa, H.: Chondroitin sulfate-E fine-tunes osteoblast differentiation via ERK1/2, Smad3 and Smad1/5/8 signaling by binding to N-cadherin and cadherin-11. Biochem. Biophys. Res. Commun. 420, 523-529 (2012)
40. Priglinger, U.; Geiger, M.; Bielek, E.; Vanyek, E.; Binder, B.R.: Binding of urinary protein C inhibitor to cultured human epithelial kidney tumor cells (TCL-598). The role of glycosaminoglycans present on the luminal cell surface. J. Biol. Chem. 269, 14705-14710 (1994)
41. Rein, C.M.; Desai, U.R.; Church, F.C.: Serpin-glycosaminoglycan interactions. Methods Enzymol. 501, 105-137 (2011)
42. Liaw, P.C.; Becker, D.L.; Stafford, A.R.; Fredenburgh, J.C.; Weitz, J.I.: Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. J. Biol. Chem. 276, 20959-20965 (2001)
43. Fernandez, J.A.; Petaja, J.; Griffin, J.H.: Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C. Thromb. Haemost. 82, 1462-1468 (1999)
44. Capila, I.; VanderNoot, V.A.; Mealy, T.R.; Seaton, B.A.; Linhardt, R.J.: Interaction of heparin with annexin V. FEBS Lett. 446, 327-330 (1999)
45. Xu, R.; Ori, A.; Rudd, T.R.; et al.: Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity. J. Biol. Chem. 287, 40061-40073 (2012)
46. Deepa, S.S.; Umehara, Y.; Higashiyama, S.; Itoh, N.; Sugahara, K.: Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J. Biol. Chem. 277, 43707-43716 (2002)
47. Penc, S.F.; Pomahac, B.; Winkler, T.; et al.: Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J. Biol. Chem. 273, 28116-28121 (1998)
48. Weyers, A.; Yang, B.; Solakyildirim, K.; et al.: Isolation of bovine corneal keratan sulfate and its growth factor and morphogen binding. FEBS J. 280, 2285-2293 (2013)
49. Aviezer, D.; Yayon, A.: Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc. Natl. Acad. Sci. U. S. A. 91, 12173-12177 (1994)
50. Garcia-Olivas, R.; Hoebeke, J.; Castel, S.; et al.: Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans. Histochem. Cell Biol. 120, 371-382 (2003)
51. Hildebrand, A.; Romaris, M.; Rasmussen, L.M.; et al.: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem. J. 302(Pt 2), 527-534 (1994)
52. Lee, M.J.: Heparin inhibits activation of latent transforming growth factor-beta1. Pharmacology 92, 238-244 (2013)
53. Lyon, M.; Deakin, J.A.; Gallagher, J.T.: The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J. Biol. Chem. 277, 1040-1046 (2002)
54. Miyazaki, T.; Miyauchi, S.; Tawada, A.; Anada, T.; Matsuzaka, S.; Suzuki, O.: Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J. Cell. Physiol. 217, 769-777 (2008)
55. Paine-Saunders, S.; Viviano, B.L.; Economides, A.N.; Saunders, S.: Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. J. Biol. Chem. 277, 2089-2096 (2002)
56. Teran, M.; Nugent, M.A.: Synergistic binding of vascular endothelial growth factor-A and its receptors to heparin selectively modulates complex affinity. J. Biol. Chem. 290, 16451-16462 (2015)
57. Taylor, K.R.; Rudisill, J.A.; Gallo, R.L.: Structural and sequence motifs in dermatan sulfate for promoting fibroblast growth factor-2 (FGF-2) and FGF-7 activity. J. Biol. Chem. 280, 5300-5306 (2005)
58. Iozzo, R.V.; Moscatello, D.K.; McQuillan, D.J.; Eichstetter, I.: Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 274, 4489-4492 (1999)
59. Brooks, B.; Briggs, D.M.; Eastmond, N.C.; Fernig, D.G.; Coleman, J.W.: Presentation of IFN-gamma to nitric oxide-producing cells: a novel function for mast cells. J. Immunol. 164, 573-579 (2000)
60. Camejo, E.H.; Rosengren, B.; Camejo, G.; Sartipy, P.; Fager, G.; Bondjers, G.: Interferon gamma binds to extracellular matrix chondroitin-sulfate proteoglycans, thus enhancing its cellular response. Arterioscler. Thromb. Vasc. Biol. 15, 1456-1465 (1995)
61. Lortat-Jacob, H.; Grimaud, J.A.: Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett. 280, 152-154 (1991)
62. Spratte, J.; Schonborn, M.; Treder, N.; Bornkessel, F.; Zygmunt, M.; Fluhr, H.: Heparin modulates chemokines in human endometrial stromal cells by interaction with tumor necrosis factor alpha and thrombin. Fertil. Steril. 103, 1363-1369 (2015)
63. Tully, S.E.; Rawat, M.; Hsieh-Wilson, L.C.: Discovery of a TNF-alpha antagonist using chondroitin sulfate microarrays. J. Am. Chem. Soc. 128, 7740-7741 (2006)
64. Nadanaka, S.; Kinouchi, H.; Taniguchi-Morita, K.; Tamura, J.; Kitagawa, H.: Down-regulation of chondroitin 4-O-sulfotransferase-1 by Wnt signaling triggers diffusion of Wnt-3a. J. Biol. Chem. 286, 4199-4208 (2011)
65. Reichsman, F.; Smith, L.; Cumberledge, S.: Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J. Cell Biol. 135, 819-827 (1996)
66. Gotte, M.: Syndecans in inflammation. FASEB J. 17, 575-591 (2003)
67. Kuschert, G.S.; Coulin, F.; Power, C.A.; et al.: Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38, 12959-12968 (1999)
68. Proudfoot, A.E.; Fritchley, S.; Borlat, F.; et al.: The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem. 276, 10620-10626 (2001)
69. Kawashima, H.; Atarashi, K.; Hirose, M.; et al.: Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J. Biol. Chem. 277, 12921-12930 (2002)
70. Kunze, G.; Gehrcke, J.P.; Pisabarro, M.T.; Huster, D.: NMR characterization of the binding properties and conformation of glycosaminoglycans interacting with interleukin-10. Glycobiology 24, 1036-1049 (2014)
71. Salanga, C.L.; Handel, T.M.: Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317, 590-601 (2011)
72. Poluri, K.M.; Joseph, P.R.; Sawant, K.V.; Rajarathnam, K.: Molecular basis of glycosaminoglycan heparin binding to the chemokine CXCL1 dimer. J. Biol. Chem. 288, 25143-25153 (2013)
73. Rajasekaran, D.; Keeler, C.; Syed, M.A.; et al.: A model of GAG/MIP-2/CXCR2 interfaces and its functional effects. Biochemistry 51, 5642-5654 (2012)
74. Krohn, S.; Garin, A.; Gabay, C.; Proudfoot, A.E.: The activity of CCL18 is principally mediated through interaction with glycosaminoglycans. Front. Immunol. 4, 193 (2013)
75. Schmidt, G.; Robenek, H.; Harrach, B.; et al.: Interaction of small dermatan sulfate proteoglycan from fibroblasts with fibronectin. J. Cell Biol. 104, 1683-1691 (1987)
76. Walker, A.; Gallagher, J.T.: Structural domains of heparan sulphate for specific recognition of the C-terminal heparin-binding domain of human plasma fibronectin (HEPII). Biochem. J. 317(Pt 3), 871-877 (1996)
77. Nunes, S.S.; Outeiro-Bernstein, M.A.; Juliano, L.; et al.: Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1. J. Cell. Physiol. 214, 828-837 (2008)
78. Winnemoller, M.; Schon, P.; Vischer, P.; Kresse, H.: Interactions between thrombospondin and the small proteoglycan decorin: interference with cell attachment. Eur. J. Cell Biol. 59, 47-55 (1992)
79. Saito, Y.; Imazeki, H.; Miura, S.; et al.: A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J. Biol. Chem. 282, 34929-34937 (2007)
80. Duensing, T.D.; Putten, J.P.: Vitronectin binds to the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge. Biochem. J. 334(Pt 1), 133-139 (1998)
81. Utani, A.; Nomizu, M.; Matsuura, H.; et al.: A unique sequence of the laminin alpha 3 G domain binds to heparin and promotes cell adhesion through syndecan-2 and -4. J. Biol. Chem. 276, 28779-28788 (2001)
82. Iozzo, R.V.: The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 32, 141-174 (1997)
83. Elefteriou, F.; Exposito, J.Y.; Garrone, R.; Lethias, C.: Binding of tenascin-X to decorin. FEBS Lett. 495, 44-47 (2001)
84. Edelberg, J.M.; Pizzo, S.V.: Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. Biochemistry 29, 5906-5911 (1990)
85. Nozik-Grayck, E.; Suliman, H.B.; Piantadosi, C.A.: Extracellular superoxide dismutase. Int. J. Biochem. Cell Biol. 37, 2466-2471 (2005)
86. Marshall, L.J.; Ramdin, L.S.; Brooks, T.; DPhil, P.C.; Shute, J.K.: Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J. Immunol. 171, 2057-2065 (2003)
87. Frommherz, K.J.; Faller, B.; Bieth, J.G.: Heparin strongly decreases the rate of inhibition of neutrophil elastase by alpha 1-proteinase inhibitor. J. Biol. Chem. 266, 15356-15362 (1991)
88. Ermolieff, J.; Boudier, C.; Laine, A.; Meyer, B.; Bieth, J.G.: Heparin protects cathepsin G against inhibition by protein proteinase inhibitors. J. Biol. Chem. 269, 29502-29508 (1994)
89. Frick, I.M.; Schmidtchen, A.; Sjobring, U.: Interactions between M proteins of Streptococcus pyogenes and glycosaminoglycans promote bacterial adhesion to host cells. Eur. J. Biochem. 270, 2303-2311 (2003)
90. Liu, J.; Shriver, Z.; Pope, R.M.; et al.: Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J. Biol. Chem. 277, 33456-33467 (2002)
91. Fortune, D.E.; Lin, Y.P.; Deka, R.K.; et al.: Identification of lysine residues in the Borrelia burgdorferi DbpA adhesin required for murine infection. Infect. Immun. 82, 3186-3198 (2014)
92. Fischer, J.R.; Parveen, N.; Magoun, L.; Leong, J.M.: Decorin-binding proteins A and B confer distinct mammalian cell type-specific attachment by Borrelia burgdorferi, the Lyme disease spirochete. Proc. Natl. Acad. Sci. U. S. A. 100, 7307-7312 (2003)
93. Wang, X.: Solution structure of decorin-binding protein A from Borrelia burgdorferi. Biochemistry 51, 8353-8362 (2012)
94. Fry, E.E.; Lea, S.M.; Jackson, T.; et al.: The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 18, 543-554 (1999)
95. Seema, Jain, S.K.: Molecular mechanism of pathogenesis of dengue virus: entry and fusion with target cell. Indian J. Clin. Biochem 20, 92-103 (2005)
96. Harrop, H.A.; Coombe, D.R.; Rider, C.C.: Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 8, 183-192 (1994)
97. Goel, S.; Gowda, D.C.: How specific is Plasmodium falciparum adherence to chondroitin 4-sulfate? Trends Parasitol. 27, 375-381 (2011)
98. Mardberg, K.; Trybala, E.; Tufaro, F.; Bergstrom, T.: Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J. Gen. Virol. 83, 291-300 (2002)
99. Hamazaki, H.: Ca2 + -mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J. Biol. Chem. 262, 1456-1460 (1987)
100. Ben-Zaken, O.; Tzaban, S.; Tal, Y.; et al.: Cellular heparan sulfate participates in the metabolism of prions. J. Biol. Chem. 278, 40041-40049 (2003)
101. Patey, S.J.; Edwards, E.A.; Yates, E.A.; Turnbull, J.E.: Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics. Neurodegener Dis 5, 197-199 (2008)
102. Liu, I.H.; Uversky, V.N.; Munishkina, L.A.; Fink, A.L.; Halfter, W.; Cole, G.J.: Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology 15, 1320-1331 (2005)
103. Camejo, G.; Hurt-Camejo, E.; Wiklund, O.; Bondjers, G.: Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 139, 205-222 (1998)
104. Olivecrona, T.; gtsson-Olivecrona, G.; Ostergaard, P.; Liu, G.; Chevreuil, O.; Hultin, M.: New aspects on heparin and lipoprotein metabolism. Haemostasis 23(Suppl 1), 150-160 (1993)
105. Dong, J.; Peters-Libeu, C.A.; Weisgraber, K.H.; et al.: Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry 40, 2826-2834 (2001)
106. Kovanen, P.T.; Pentikainen, M.O.: Decorin links low-density lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc. Med. 9, 86-91 (1999)
107. Mizumoto, S.; Takahashi, J.; Sugahara, K.: Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells. J. Biol. Chem. 287, 18985-18994 (2012)
108. Johnson, G.B.; Brunn, G.J.; Kodaira, Y.; Platt, J.L.: Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 168, 5233-5239 (2002)
109. Termeer, C.; Benedix, F.; Sleeman, J.; et al.: Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 195, 99-111 (2002)
110. Lesley, J.; Gal, I.; Mahoney, D.J.; et al.: TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J. Biol. Chem. 279, 25745-25754 (2004)
111. Fisher, D.; Xing, B.; Dill, J.; et al.: Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J. Neurosci. 31, 14051-14066 (2011)
112. Shen, Y.; Tenney, A.P.; Busch, S.A.; et al.: PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 326, 592-596 (2009)
113. Dickendesher, T.L.; Baldwin, K.T.; Mironova, Y.A.; et al.: NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat. Neurosci. 15, 703-712 (2012)
114. Dick, G.; Tan, C.L.; Alves, J.N.; et al.: Semaphorin 3A binds to the perineuronal nets via chondroitin sulfate type E motifs in rodent brains. J. Biol. Chem. 288, 27384-27395 (2013)
115. Imberty, A.; Lortat-Jacob, H.; Perez, S.: Structural view of glycosaminoglycan-protein interactions. Carbohydr. Res. 342, 430-439 (2007)
116. Raman, R.; Sasisekharan, V.; Sasisekharan, R.: Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem. Biol. 12, 267-277 (2005)
117. Gandhi, N.S.; Mancera, R.L.: The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 72, 455-482 (2008)
118. Capila, I.; Linhardt, R.J.: Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 41, 391-412 (2002)
119. Xu, D.; Esko, J.D.: Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 83, 129-157 (2014)
120. Iwaki, J.; Minamisawa, T.; Tateno, H.; et al.: Desulfated galactosaminoglycans are potential ligands for galectins: evidence from frontal affinity chromatography. Biochem. Biophys. Res. Commun. 373, 206-212 (2008)
121. Desai, U.R.; Petitou, M.; Bjork, I.; Olson, S.T.: Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J. Biol. Chem. 273, 7478-7487 (1998)
122. Jin, L.; Abrahams, J.P.; Skinner, R.; Petitou, M.; Pike, R.N.; Carrell, R.W.: The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U. S. A. 94, 14683-14688 (1997)
123. Streusand, V.J.; Bjork, I.; Gettins, P.G.; Petitou, M.; Olson, S.T.: Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin. Role of the antithrombin binding pentasaccharide in heparin rate enhancement. J. Biol. Chem. 270, 9043-9051 (1995)
124. Wang, L.; Fuster, M.; Sriramarao, P.; Esko, J.D.: Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat. Immunol. 6, 902-910 (2005)
125. Poluri, K.M.: Chemokines: the holy messengers of leukocyte trafficking. Austin J Biotechnol. Bioeng. 1, 1-3 (2014)
126. Schlorke, D.; Thomas, L.; Samsonov, S.A.; Huster, D.; Arnhold, J.; Pichert, A.: The influence of glycosaminoglycans on IL-8-mediated functions of neutrophils. Carbohydr. Res. 356, 196-203 (2012)
127. Axelsson, J.; Xu, D.; Kang, B.N.; et al.: Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 120, 1742-1751 (2012)
128. Taylor, K.R.; Gallo, R.L.: Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 20, 9-22 (2006)
129. Jayson, G.C.; Hansen, S.U.; Miller, G.J.; et al.: Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology. Chem. Commun. (Camb.) 51, 13846-13849 (2015)
130. Honorio, J.C.; Bruns, R.F.; Grundtner, L.F.; et al.: Diastrophic dysplasia: prenatal diagnosis and review of the literature. Sao Paulo Med. J. 131, 127-132 (2013)
131. Coppa, G.V.; Gabrielli, O.; Buzzega, D.; et al.: Composition and structure elucidation of human milk glycosaminoglycans. Glycobiology 21, 295-303 (2011)
132. Nikitovic, D.; Assouti, M.; Sifaki, M.; et al.: Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines. Int. J. Biochem. Cell Biol. 40, 72-83 (2008)
133. Zhang, G.L.; Zhang, X.; Wang, X.M.; Li, J.P.: Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer's disease. Biomed. Res. Int 2014, 516028 (2014)
134. Conde-Knape, K.: Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab. Res. Rev. 17, 412-421 (2001)
135. Warkentin, T.E.: Heparin-induced thrombocytopenia. Curr. Opin. Crit. Care 21, 576-585 (2015)
136. Andrade, F.; miz-Echevarria, L.; Llarena, M.; Couce, M.L.: Sanfilippo syndrome: overall review. Pediatr. Int. 57, 331-338 (2015)
137. Lindahl, U.; Kjellen, L.: Pathophysiology of heparan sulphate: many diseases, few drugs. J. Intern. Med. 273, 555-571 (2013)
138. Baron, M.J.; Bolduc, G.R.; Goldberg, M.B.; Auperin, T.C.; Madoff, L.C.: Alpha C protein of group B Streptococcus binds host cell surface glycosaminoglycan and enters cells by an actin-dependent mechanism. J. Biol. Chem. 279, 24714-24723 (2004)
139. Park, P.W.; Pier, G.B.; Hinkes, M.T.; Bernfield, M.: Exploitation of syndecan-1 shedding by pseudomonas aeruginosa enhances virulence. Nature 411, 98-102 (2001)
140. Trowbridge, J.M.; Gallo, R.L.: Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 12, 117R-125R (2002)
141. Lensen, J.F.; van der Vlag, J.; Versteeg, E.M.; et al.: Differential expression of specific dermatan sulfate domains in renal pathology. PLoS One 10, e0134946 (2015)
142. Schmidtchen, A.; Frick, I.M.; Bjorck, L.: Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin. Mol. Microbiol. 39, 708-713 (2001)
143. Hinek, A.; Wilson, S.E.: Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am. J. Pathol. 156, 925-938 (2000)
144. Dyck, S.M.; Karimi-Abdolrezaee, S.: Chondroitin sulfate proteoglycans: key modulators in the developing and pathologic central nervous system. Exp. Neurol. 269, 169-187 (2015)
145. Galtrey, C.M.; Fawcett, J.W.: The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res. Rev. 54, 1-18 (2007)
146. ten Dam, G.B.; van de Westerlo, E.M.; Purushothaman, A.; et al.: Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am. J. Pathol. 171, 1324-1333 (2007)
147. Quantock, A.J.; Young, R.D.; Akama, T.O.: Structural and biochemical aspects of keratan sulphate in the cornea. Cell. Mol. Life Sci. 67, 891-906 (2010)
148. Dung, V.C.; Tomatsu, S.; Montano, A.M.; et al.: Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol. Genet. Metab. 110, 129-138 (2013)
149. Dyer, D.P.; Thomson, J.M.; Hermant, A.; et al.: TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J. Immunol. 192, 2177-2185 (2014)
150. Fraser, J.R.; Laurent, T.C.; Laurent, U.B.: Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242, 27-33 (1997)
151. Karbownik, M.S.; Nowak, J.Z.: Hyaluronan: towards novel anti-cancer therapeutics. Pharmacol. Rep. 65, 1056-1074 (2013)
152. Heldin, P.; Basu, K.; Olofsson, B.; Porsch, H.; Kozlova, I.; Kahata, K.: Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J. Biochem. 154, 395-408 (2013)
153. Liang, J.; Jiang, D.; Noble, P.W.: Hyaluronan as a therapeutic target in human diseases. Adv. Drug Deliv. Rev. (2015) (In press)
154. Bame, K.J.: Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 11, 91R-98R (2001)
155. Migliorini, E.; Thakar, D.; Kuhnle, J. et al.: Cytokines and growth factors cross-link heparan sulfate. Open. Biol. 5, (2015)
156. Kato, M.; Wang, H.; Kainulainen, V.; et al.: Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4, 691-697 (1998)
157. Xu, D.; Young, J.; Song, D.; Esko, J.D.: Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 286, 41736-41744 (2011)
158. Nenci, G.G.: Dermatan sulphate as an antithrombotic drug. Pathophysiol. Haemost. Thromb. 32, 303-307 (2002)
159. Bradbury, E.J.; Moon, L.D.; Popat, R.J.; et al.: Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416, 636-640 (2002)
160. Moon, L.D.; Asher, R.A.; Rhodes, K.E.; Fawcett, J.W.: Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat. Neurosci. 4, 465-466 (2001)
161. Davies, J.E.; Tang, X.; Denning, J.W.; Archibald, S.J.; Davies, S.J.: Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries. Eur. J. Neurosci. 19, 1226-1242 (2004)
162. Henson, F.M.; Getgood, A.M.; Caborn, D.M.; McIlwraith, C.W.; Rushton, N.: Effect of a solution of hyaluronic acid-chondroitin sulfate-N-acetyl glucosamine on the repair response of cartilage to single-impact load damage. Am. J. Vet. Res. 73, 306-312 (2012)
163. Carlson, E.C.; Sun, Y.; Auletta, J.; et al.: Regulation of corneal inflammation by neutrophil-dependent cleavage of keratan sulfate proteoglycans as a model for breakdown of the chemokine gradient. J. Leukoc. Biol. 88, 517-522 (2010)
164. Kadomatsu, K.; Sakamoto, K.: Sulfated glycans in network rewiring and plasticity after neuronal injuries. Neurosci. Res. 78, 50-54 (2014)
165. Hilton, B.J.; Lang, B.T.; Cregg, J.M.: Keratan sulfate proteoglycans in plasticity and recovery after spinal cord injury. J. Neurosci. 32, 4331-4333 (2012)
166. Hayashi, M.; Kadomatsu, K.; Kojima, T.; Ishiguro, N.: Keratan sulfate and related murine glycosylation can suppress murine cartilage damage in vitro and in vivo. Biochem. Biophys. Res. Commun. 409, 732-737 (2011)
167. Miyamoto, T.; Ishii, K.; Asaka, R.; et al.: Immunohistochemical expression of keratan sulfate: a possible diagnostic marker for carcinomas of the female genital tract. J. Clin. Pathol. 64, 1058-1063 (2011)
168. Dicker, K.T.; Gurski, L.A.; Pradhan-Bhatt, S.; Witt, R.L.; Farach-Carson, M.C.; Jia, X.: Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater. 10, 1558-1570 (2014)
169. Schommer, N.N.; Muto, J.; Nizet, V.; Gallo, R.L.: Hyaluronan breakdown contributes to immune defense against group A Streptococcus. J. Biol. Chem. 289, 26914-26921 (2014)
170. Volpi, N.: Therapeutic applications of glycosaminoglycans. Curr. Med. Chem. 13, 1799-1810 (2006)
171. Migliore, A.; Granata, M.: Intra-articular use of hyaluronic acid in the treatment of osteoarthritis. Clin. Interv. Aging 3, 365-369 (2008)
172. Liu, L.; Liu, Y.; Li, J.; Du, G.; Chen, J.: Microbial production of hyaluronic acid: current state, challenges, and perspectives. Microb. Cell Fact. 10, 99 (2011)
173. Simanek, V.; Kren, V.; Ulrichova, J.; Gallo, J.: The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals? Biomed. Pap. Med. Fac. Univ Palacky. Olomouc. Czech. Repub. 149, 51-56 (2005)
174. Fardellone, P.; Zaim, M.; Saurel, A.S.; Maheu, E.: Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol. J. 7, 1-12 (2013)
175. Varkey, M.; Ding, J.; Tredget, E.E.: Advances in skin substitutes-potential of tissue engineered skin for facilitating anti-fibrotic healing. J. Funct. Biomater. 6, 547-563 (2015)
176. Barbanti, M.; Calanni, F.; Babbini, M.; et al.: Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb. Res. 71, 417-422 (1993)
177. Linhardt, R.J.: Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J. Med. Chem. 46, 2551-2564 (2003)
178. Gallo, R.L.; Bucay, V.W.; Shamban, A.T.; et al.: The potential role of topically applied heparan sulfate in the treatment of photodamage. J. Drugs Dermatol. 14, 669-674 (2015)
179. Merli, G.J.; Groce, J.B.: Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P.T. 35, 95-105 (2010)
180. Petitou, M.; van Boeckel, C.A.: A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed Engl 43, 3118-3133 (2004)
181. Manenti, L.; Tansinda, P.; Vaglio, A.: Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert Opin. Pharmacother. 9, 2175-2180 (2008)
182. Harenberg, J.: Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb. Haemost. 102, 811-815 (2009)
183. Khachigian, L.M.; Parish, C.R.: Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc. Drug Rev. 22, 1-6 (2004)
184. Mahajan, P.; Sodhi, K.S.; Pandey, R.; Singh, J.: Glycotherapeutics: clinical implications. IJAPBC 3, 786-795 (2014)
185. Lawrence, R.; Brown, J.R.; Lorey, F.; Dickson, P.I.; Crawford, B.E.; Esko, J.D.: Glycan-based biomarkers for mucopolysaccharidoses. Mol. Genet. Metab. 111, 73-83 (2014)
186. Gigante, A.; Callegari, L.: The role of intra-articular hyaluronan (Sinovial) in the treatment of osteoarthritis. Rheumatol. Int. 31, 427-444 (2011)
187. Salvatore, S.; Heuschkel, R.; Tomlin, S.; et al.: A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment. Pharmacol. Ther. 14, 1567-1579 (2000)
188. Esmaeili, M.; Berry, M.; Logan, A.; Ahmed, Z.: Decorin treatment of spinal cord injury. Neural Regen. Res. 9, 1653-1656 (2014)
189. Reed, C.C.; Waterhouse, A.; Kirby, S.; et al.: Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 1104-1110 (2005)
190. Page, C.: Heparin and related drugs: beyond anticoagulant activity. ISRN. Pharmacol 2013, 910743 (2013)
191. Ferro, V.; Fewings, K.; Palermo, M.C.; Li, C.: Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88. Carbohydr. Res. 332, 183-189 (2001)
192. Desai, U.R.: The promise of sulfated synthetic small molecules as modulators of glycosaminoglycan function. Future Med. Chem. 5, 1363-1366 (2013)
193. Adage, T.; Piccinini, A.M.; Falsone, A.; et al.: Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br. J. Pharmacol. 167, 1195-1205 (2012)
194. Al-Horani, R.A.; Gailani, D.; Desai, U.R.: Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb. Res. 136, 379-387 (2015)
195. Gesslbauer, B.; Theuer, M.; Schweiger, D.; Adage, T.; Kungl, A.J.: New targets for glycosaminoglycans and glycosaminoglycans as novel targets. Expert Rev. Proteomics 10, 77-95 (2013)
196. Harris, N.; Kogan, F.Y.; Il'kova, G.; et al.: Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties. Biochim. Biophys. Acta 1840, 245-254 (2014)
197. Scharnweber, D.; Hubner, L.; Rother, S.; et al.: Glycosaminoglycan derivatives: promising candidates for the design of functional biomaterials. J. Mater. Sci. Mater. Med. 26, 232 (2015)
198. Severin, I.C.; Soares, A.; Hantson, J.; et al.: Glycosaminoglycan analogs as a novel anti-inflammatory strategy. Front. Immunol. 3, 293 (2012)
199. Sung, H.J.; Choi, S.; Lee, J.W.; et al.: Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. Biomaterials 35, 578-589 (2014)
200. Weyers, A.; Linhardt, R.J.: Neoproteoglycans in tissue engineering. FEBS J. 280, 2511-2522 (2013)
201. Miller, T.; Goude, M.C.; McDevitt, T.C.; Temenoff, J.S.: Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. Acta Biomater. 10, 1705-1719 (2014)
202. Andreas, K.; Sittinger, M.; Ringe, J.: Toward in situ tissue engineering: chemokine-guided stem cell recruitment. Trends Biotechnol. 32, 483-492 (2014)
203. Ko, I.K.; Lee, S.J.; Atala, A.; Yoo, J.J.: In situ tissue regeneration through host stem cell recruitment. Exp. Mol. Med. 45, e57 (2013)
204. Shi, Y.; Su, J.; Roberts, A.I.; Shou, P.; Rabson, A.B.; Ren, G.: How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 33, 136-143 (2012)
205. Gulati, K.; Poluri, K.M.: Chemoattractants, scaffolds and endogenous stem cells: adorable partners of in situ tissue regeneration. Austin J. Biotechnol. Bioeng. 2 (2015) (In press)
206. Jay, S.M.; Shepherd, B.R.; Andrejecsk, J.W.; Kyriakides, T.R.; Pober, J.S.; Saltzman, W.M.: Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization. Biomaterials 31, 3054-3062 (2010)
207. Kumamoto, T.; Huang, E.K.; Paek, H.J.; et al.: Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat. Biotechnol. 20, 64-69 (2002)
208. Pacheco, D.P.; Reis, R.L.; Correlo, V.M.; Marques, A.P.: The crosstalk between tissue engineering and pharmaceutical biotechnology: recent advances and future directions. Curr. Pharm. Biotechnol. 16, 1012-1023 (2015)
209. Segers, V.F.; Tokunou, T.; Higgins, L.J.; MacGillivray, C.; Gannon, J.; Lee, R.T.: Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 116, 1683-1692 (2007)
210. Singh, A.; Suri, S.; Roy, K.: In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 30, 5187-5200 (2009)
211. Wang, Y.; Irvine, D.J.: Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres. Biomaterials 32, 4903-4913 (2011)
212. Zhao, X.; Jain, S.; Benjamin, L.H.; Gonzalez, S.; Irvine, D.J.: Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 26, 5048-5063 (2005)
213. Jin, R.; Teixeira, L.S.; Dijkstra, P.J.; van Blitterswijk, C.A.; Karperien, M.; Feijen, J.: Enzymatically-crosslinked injectable hydrogels based on biomimetic dextran-hyaluronic acid conjugates for cartilage tissue engineering. Biomaterials 31, 3103-3113 (2010)
214. Lee, I.C.; Wu, Y.C.; Cheng, E.M.; Yang, W.T.: Biomimetic niche for neural stem cell differentiation using poly-L-lysine/hyaluronic acid multilayer films. J. Biomater. Appl. 29, 1418-1427 (2015)
215. MacArthur Jr.; J.W.; Purcell, B.P.; Shudo, Y.; et al.: Sustained release of engineered stromal cell-derived factor 1-alpha from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction. Circulation 128, S79-S86 (2013)
216. Prokoph, S.; Chavakis, E.; Levental, K.R.; et al.: Sustained delivery of SDF-1alpha from heparin-based hydrogels to attract circulating pro-angiogenic cells. Biomaterials 33, 4792-4800 (2012)
217. Purcell, B.P.; Elser, J.A.; Mu, A.; Margulies, K.B.; Burdick, J.A.: Synergistic effects of SDF-1alpha chemokine and hyaluronic acid release from degradable hydrogels on directing bone marrow derived cell homing to the myocardium. Biomaterials 33, 7849-7857 (2012)
218. Yu, J.; Wang, A.; Tang, Z.; et al.: The effect of stromal cell-derived factor-1alpha/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration. Biomaterials 33, 8062-8074 (2012)
219. Wen, Y.; Grondahl, L.; Gallego, M.R.; Jorgensen, L.; Moller, E.H.; Nielsen, H.M.: Delivery of dermatan sulfate from polyelectrolyte complex-containing alginate composite microspheres for tissue regeneration. Biomacromolecules 13, 905-917 (2012)
220. Miwa, H.; Matsuda, T.: An integrated approach to the design and engineering of hybrid arterial prostheses. J. Vasc. Surg. 19, 658-667 (1994)
221. Coburn, J.M.; Gibson, M.; Monagle, S.; Patterson, Z.; Elisseeff, J.H.: Bioinspired nanofibers support chondrogenesis for articular cartilage repair. Proc. Natl. Acad. Sci. U. S. A. 109, 10012-10017 (2012)
222. Harley, B.A.; Lynn, A.K.; Wissner-Gross, Z.; Bonfield, W.; Yannas, I.V.; Gibson, L.J.: Design of a multiphase osteochondral scaffold. II. Fabrication of a mineralized collagen-glycosaminoglycan scaffold. J. Biomed. Mater. Res. A 92, 1066-1077 (2010)
223. Harley, B.A.; Lynn, A.K.; Wissner-Gross, Z.; Bonfield, W.; Yannas, I.V.; Gibson, L.J.: Design of a multiphase osteochondral scaffold III: fabrication of layered scaffolds with continuous interfaces. J. Biomed. Mater. Res. A 92, 1078-1093 (2010)
224. Kemp, M.M.; Kumar, A.; Mousa, S.; et al.: Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology 20, 455104 (2009)
225. Kemp, M.M.; Linhardt, R.J.: Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 77-87 (2010)
226. Lynn, A.K.; Best, S.M.; Cameron, R.E.; et al.: Design of a multiphase osteochondral scaffold. I. Control of chemical composition. J. Biomed. Mater. Res. A 92, 1057-1065 (2010)
227. Yeh, M.K.; Cheng, K.M.; Hu, C.S.; Huang, Y.C.; Young, J.J.: Novel protein-loaded chondroitin sulfate-chitosan nanoparticles: preparation and characterization. Acta Biomater. 7, 3804-3812 (2011)
228. Wu. J.L.; Liao, C.Y.; Zhang J.; Cheng, W.Z.; Zhou, N.; Wang, S.; Wan, Y.: Incorporation of protein-loaded microspheres into chitosan-polycaprolactone scaffolds for controlled release. Carbohydr. Polymers. 1048-1054 (2011)
229. Chen, F.M.; Lu, H.; Wu, L.A.; Gao, L.N.; An, Y.; Zhang, J.: Surface-engineering of glycidyl methacrylated dextran/gelatin microcapsules with thermo-responsive poly(N-isopropylacrylamide) gates for controlled delivery of stromal cell-derived factor-1alpha. Biomaterials 34, 6515-6527 (2013)
230. Huang, Y.C.; Liu, T.J.: Mobilization of mesenchymal stem cells by stromal cell-derived factor-1 released from chitosan/tripolyphosphate/fucoidan nanoparticles. Acta Biomater. 8, 1048-1056 (2012)
231. Qiu, X.Y.; Yang, Y.H.; Wang, L.P.; Lu, S.L.; Shao, Z.Z.; Chen, X.: Synergistic interactions during thermosensitive chitosan-beta-glycerophosphate hydrogel formation. RSC Advances 1, 282-289 (2011)
232. Muzzarelli, R.A.; Greco, F.; Busilacchi, A.; Sollazzo, V.; Gigante, A.: Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: a review. Carbohydr. Polym. 89, 723-739 (2012)
233. Schnabelrauch, M.; Scharnweber, D.; Schiller, J.: Sulfated glycosaminoglycans as promising artificial extracellular matrix components to improve the regeneration of tissues. Curr. Med. Chem. 20, 2501-2523 (2013)
234. Scott, R.A.; Panitch, A.: Glycosaminoglycans in biomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5, 388-398 (2013)
235. Wan, A.C.; Ying, J.Y.: Nanomaterials for in situ cell delivery and tissue regeneration. Adv. Drug Deliv. Rev. 62, 731-740 (2010)
236. DeAngelis, P.L.; Liu, J.; Linhardt, R.J.: Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains. Glycobiology 23, 764-777 (2013)
237. Liu, J.; Linhardt, R.J.: Chemoenzymatic synthesis of heparan sulfate and heparin. Nat. Prod. Rep. 31, 1676-1685 (2014)
238. n oligosccharides from 16-mer to 40-mer. Chem. Sci. 6, 6158-6164 (2015)
239. Laguri, C.; Sapay, N.; Simorre, J.P.; et al.: 13C-labeled heparan sulfate analogue as a tool to study protein/heparan sulfate interactions by NMR spectroscopy: application to the CXCL12alpha chemokine. J. Am. Chem. Soc. 133, 9642-9645 (2011)
240. Pomin, V.H.: A Dilemma in the glycosaminoglycan-based therapy: synthetic or naturally unique molecules? Med. Res. Rev. 35, 1195-1219 (2015)